Response to Tomao, Panici, and Tomao
- PMID: 31287552
- PMCID: PMC7156924
- DOI: 10.1093/jnci/djz140
Response to Tomao, Panici, and Tomao
Comment on
-
Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition.J Natl Cancer Inst. 2020 Feb 1;112(2):161-169. doi: 10.1093/jnci/djz080. J Natl Cancer Inst. 2020. PMID: 31076742 Free PMC article.
-
RE: Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition.J Natl Cancer Inst. 2020 Apr 1;112(4):423-424. doi: 10.1093/jnci/djz138. J Natl Cancer Inst. 2020. PMID: 31287551 Free PMC article. No abstract available.
References
-
- National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast and Ovarian (Version 3.2019, January 18, 2019) 2019. https://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf. Accessed June 25, 2019.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical